2026 Immunization Vaccines 
Pharmaceutical Technology
JULY 18, 2022
GlaxoSmithKline (GSK) has signed an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to aid in protecting adults and children in the country. The company intends to supply both vaccines from its 230,000ft² Sainte-Foy facility in Quebec. .
Express Pharma
MARCH 20, 2023
India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government will float a global tender in April 2023 to procure HPV vaccines. per cent from 0.43 million in 2021 to 0.54
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 7, 2022
The approval is some relief for Sanofi after a crop of pipeline disappointments last year, with Evaluate estimating the drug could make more than $500 million in sales in 2026. It is also being developed for other indications including immune thrombocytopenic purpura.
PharmaShots
FEBRUARY 21, 2023
threshold by 2026. Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines.
Big Molecule Watch
DECEMBER 13, 2024
Currently in preclinical development, DB-1324 was developed using DualityBios proprietary and clinically validated Duality Immune Toxin Antibody Conjugate platform. The facility will create 200 jobs and is set to be fully operational by mid-2026. A biologics license application for Zeno is also under review by the FDA.
pharmaphorum
OCTOBER 21, 2020
Merck & Co has built more momentum behind its attempt to depose Pfizer’s blockbuster pneumococcal conjugate vaccine Prevnar 13, with two new phase 3 trials backing its rival shot V114. It reiterated its plans to file for approval of the vaccine before the end of the year in the US.
Expert insights. Personalized for you.
64 
Let's personalize your content